Liftstream is an executive search recruitment company in the life sciences sector
Executive Recruitment Roundup – July
Authored by Liftstream
Posted in Executive Appointments, Recruitment Market
Tagged Abingworth, ARIAD Pharmaceuticals, Baxter BioScience, board appointment, Boston Therapeutics, Cary Pfeffer, CEO, Chief Medical Officer, executive appointment, Glide Pharma, John Orloff, Jounce Therapeutics, Ken Hass, Louis O'Dea, Marck Voigrt, Merck Serono, Moderna Therapeutics, Oxford Immunotec, QChip, Radius health, regulatory affairs, Richard Bungay, Richard Murray, Robert Pietrusko, Shire, Third Rock Ventures, Timothy Haines, Tony Mills, Vin Miles, Viropharma, Voyager Therpaeutics, Yan Moore
Leave a comment
NED candidate selected as Chairman of Targacept
Authored by Karl Simpson
Posted in Pharmaceutical business, Recruitment Market
Tagged Abingworth, Alzehimers, Board of Directors, Chairman, clinical trial, executive, Georgia Venture Partners, John Richard, leader, leadership, Liftstream, Mark Skaletsky, nervous disorders, Phase4 Partners, Stephen Hill, Targacept, TC-5619
Leave a comment
Prosensa & GSK pool resources to drive Drisapersen in Duchenne
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged Abingworth, David Mott, DMD, Drisapersen, Duchenne, Dystrophin, Exon 51, Genzyme, GSK, GSK’s Centre of Excellence for External Drug Discovery, Hans Schikan, Henri Termeer, Huntington's, Leiden University Medical Center, Massachusetts, MedImmune, mRNA, New Enterprise Associates (NEA), Phase II, PRO051, Prosensa, The New England Journal of Medicine
Leave a comment
Roche Snags Phase III Agromegaly Drug from Chiasma
Roche have announced they have acquired the rights to a phase III oral Agromegaly drug Octreolin from, Israeli biotech, Chiasma. Agromegaly is a rare progressive disease caused by the over production of growth hormone resulting in severe disfigurement. Agromegaly is estimated to occur in approximately 6 in every 100,000 people.
Posted in M&A Finance and Funding
Tagged Abingworth, Agromegaly, Chiasma, EMA, FDA, MAA, MPM Capital, Octreolin, Orphan Drug, Phase III, Roche, Series D
Leave a comment